- Home
- RRR vs ZLAB Comparison
RRR vs ZLAB Comparison
Compare RRR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | ZLAB |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RRR | ZLAB |
|---|---|---|
| Price | $50.26 | $25.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $69.69 | $49.60 |
| AVG Volume (30 Days) | ★ 1.0M | 760.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | 23.32 | ★ 38.46 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $2,011,483,000.00 | $460,156,000.00 |
| Revenue This Year | $3.41 | $9.75 |
| Revenue Next Year | $4.62 | $26.03 |
| P/E Ratio | $36.04 | ★ N/A |
| Revenue Growth | 3.74 | ★ 15.33 |
| 52 Week Low | $47.78 | $15.96 |
| 52 Week High | $68.99 | $34.72 |
Technical Indicators
Market Signals| Indicator | RRR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 55.31 |
| Support Level | N/A | $24.81 |
| Resistance Level | $59.20 | $27.20 |
| Average True Range (ATR) | 1.83 | 0.82 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 29.11 | 63.71 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.